Skip to content
value.today
Oragenics, Inc. logo

Oragenics, Inc.

UAVP.F
$18 Mlast known market cap, Dec 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-10 M
SEC filing
Employees
—

Oragenics, Inc. in brief

Oragenics, Inc. is a listed company in the Biotechnology industry, based in Lakewood Ranch, Florida, USA. Its last known market value was $18 M (December 2022); there is no current figure. Its shares trade under the symbol UAVP.F (Frankfurt).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Oragenics, Inc. timeline

2 events, 2002–2022
  1. 2002
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2022
  4. 💰
    Record revenue of $0 million
    FY2022, the highest of the 3 years on record.

Events of Oragenics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$16 M$32 M$49 M$65 M

World rank over time

▼ down 4,145 places since 2022
2022-01-07: #25547#25,54720222022-12-25: #29692#29,6922022

Rank in USA: #4,797 (Jan 2022) · #5,334 (Dec 2022)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
—
Net margin
—
Operating margin
—
Return on equity
-118.8%
Liabilities / assets
17.8%
Revenue growth
-69.2%
R&D / revenue
38725.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-10M—FY18Fiscal year ending Dec 2019: revenue —, net income $-16M—FY19Fiscal year ending Dec 2020: revenue —, net income $-26M—FY20Fiscal year ending Dec 2021: revenue $0M, net income $-16M$0MFY21Fiscal year ending Dec 2022: revenue $0M, net income $-14M$0MFY22Fiscal year ending Dec 2023: revenue $0M, net income $-21M$0MFY23Fiscal year ending Dec 2024: revenue —, net income $-11M—FY24Fiscal year ending Dec 2025: revenue —, net income $-10M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-9M$-10M—
Dec 2024——$-11M$-11M—
Dec 2023$0M-69.2%$-21M$-21M-51650.0%
Dec 2022$0M+44.4%$-14M$-14M-10992.3%
Dec 2021$0M—$-16M$-16M-17455.6%
Dec 2020——$-27M$-26M—
Dec 2019——$-16M$-16M—
Dec 2018——$-10M$-10M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-9M——$-4.56—
Dec 2024$-9M——$-47.88—
Dec 2023$-7M——$-9.18—
Dec 2022$-15M$0M$-15M$-7.11—
Dec 2021$-13M$0M$-14M$-0.14—
Dec 2020$-17M——$-0.47—
Dec 2019$-13M$0M$-13M$-0.37—
Dec 2018$-9M$0M$-9M$-0.87—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-3M—Dec ’24Three months to Mar 2025: revenue —, net income $-2M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-3M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-2M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-3M—Jun ’26Three months to Sep 2026: revenue —, net income $-3M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Oragenics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-9 M
Net income
$-10 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$10 M
Total liabilities
$2 M
Total equity
$8 M

As of December-2025

Insider trading at Oragenics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$197
1 sale, 1 insider
Net, 12 months
-$197
open market only
Insiders on file
20
since
-$74 K$0Nov 2023: bought $0 (0 trades), sold $12 K (1 trades)Nov 23Dec 2024: bought $0 (0 trades), sold $1 K (2 trades)DecJun 2025: bought $0 (0 trades), sold $74 K (4 trades)JunDec 2025: bought $0 (0 trades), sold $197 (1 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Oragenics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Fred TellingDirectorSellamended-210$0.940$197948Form 4/A
filed Fred TellingDirectorSell-210$0.940$19734,538Form 4
filed Odyssey Health, Inc.10% ownerSell-5,044$4.260$21 K0Form 4
filed Odyssey Health, Inc.10% ownerSell-2,000$4.460$9 K5,044Form 4
filed Odyssey Health, Inc.10% ownerSell-5,000$4.450$22 K7,044Form 4
filed Odyssey Health, Inc.10% ownerSell-5,000$4.270$21 K12,044Form 4
filed Robert C. KoskiDirectorConversionindirect+5,000——23,367Form 4
filed Alan W. DuntonDirectorSell-66$0.360$2425,623Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Oragenics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
835,778
19.6% of shares · 40.07 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split

Trading halts

  • 2025-07-01 12:02 UTC, code T3, resumed 12:50 UTC
  • 2025-06-03 13:45 UTC, code M, resumed 13:50 UTC
  • 2025-06-03 13:39 UTC, code M, resumed 13:44 UTC
  • 2025-06-03 13:33 UTC, code M, resumed 13:38 UTC

Fails to deliver

  • : 128 shares at $0.37
  • : 4,957 shares at $0.37
  • : 133 shares at $0.40
  • : 133 shares at $0.42
  • : 3,566 shares at $0.41

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Oragenics, Inc. scorecard#

Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.56 vs -47.88Diluted EPS -4.56 in fiscal 2025 against -47.88 the year before (report's currency).
    • ✓Net income higher than five years earlier-$10 M-$10 M in fiscal 2025 against -$26 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$10 MNet income -$10 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-243.9%-243.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Oragenics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Oragenics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue——0.00.10.1———00
Cost of revenue————————00
Gross profit————————00
Research and development2.44.115101122126.03.54.8
General and administrative7.06.45.54.5r5.34.53.84.03.23.8
Operating expenses9.4112115r16271610.06.78.5
Operating income−9.4−11−21−14r−16−27−16−10.0−6.7−8.5
Interest and finance income0.20.00.20.10.10.10.30.10.00.0
Interest expense and finance costs0.80.00.00.00.00.00.00.00.20.0
Other non-operating income (expense)−0.6−0.00.20.1r0.10.20.30.1−0.00.0
Income before tax−10.0−11−21−14−16−26−16−9.9−6.7−8.5
Income tax−0.1——————000
Income from continuing operations————————−6.7−8.5
Income from discontinued operations—————————1.5
Net income attributable to shareholders−9.8−11−21−14−16−26−16−9.9−6.7−7.0
Earnings per share, basic-4.56-47.88r-9.18-7.11-8.09r-0.47-0.37-0.87-1.37-1.57r
Earnings per share, diluted-4.56-47.88r-9.18-7.11-0.14-0.47-0.37-0.87-1.37-1.57r
Shares, weighted average (basic)2.20.2r2.22.01.9r57————
Shares, weighted average (diluted)2.20.2r2.22.01135742134.94.5r
Balance sheet
Cash and cash equivalents4.40.93.511271818206.24.1
Short-term investments4.0—————————
Receivables—————————0
Inventory—————————0
Other current assets1.60.60.42.9r0.40.30.61.71.00.1
Current assets101.53.914r281819227.24.2
Property, plant and equipment——00.10.00.00.10.10.00.1
Right-of-use (leased) assets——0.00.30.50.70.8———
Total assets101.55.015281920227.24.3
Accounts payable1.61.11.20.20.9r0.3r1.2r0.8r0.6r0.5r
Customer deposits———0.00.0—————
Current liabilities——1.81.61.41.31.91.20.91.3
Lease liabilities (non-current)———0.20.30.50.7———
Non-current liabilities———0.20.30.50.7———
Total liabilities1.81.71.8———————
Retained earnings−227−217−206−186−171−154−127−111−101−95
Shareholders' equity8.3−0.23.213261717216.33.0
Total liabilities and equity101.55.015281920227.24.3
Shares outstanding4.30.4r3.12.02.0r9246294.94.9r
Cash-flow statement
Depreciation and amortization——0.00.00.00.10.10.00.10.1
Share-based compensation0.60.51.00.71.71.50.61.0——
Cash from operating activities−9.2−8.6−7.3−15−13−17−13−9.1−6.4−7.1
Capital expenditure———−0.1−0.0—−0.0−0.1—−0.0
Cash from investing activities——−0.9−0.1−0.0—−0.0−0.1—1.7
Debt issued2.2—————————
Shares issued2.66.7—0.12711—14—2.6
Cash from financing activities176.00.3−0.5231611238.44.5
Change in cash7.5−2.6−7.9−169.6−0.6−1.9142.1−0.9
Report10-K10-K10-K10-K10-K10-K/A10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Oragenics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 1 subsidiaries on file.

Oragenics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Oragenics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$609 K
Other top executives, average
$609 K
the CEO earned 1× this
$100 invested is now
$1
Oragenics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$609 K$407 K$609 K$1
2024Chief executive$745 K$280 K$276 K—

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Oragenics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 5 · Material agreement 6 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2

Oragenics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Directors and officersMaterial agreementShareholder vote8-K
Material agreement8-K
Directors and officers8-K
Delisting noticeMaterial agreement8-K
Directors and officers8-K
Material agreementShareholder rights changedBylaws or fiscal year changed8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officersMaterial agreementShareholder vote8-K
Directors and officersMaterial agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 28, 2026

Acquisitions and funding#

5 private funding rounds before listing

Private share sales · funding history

Private share sales of Oragenics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$5 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Apr 2018$2 MPrivate placement after listingUnder $2 million2equity, optionsSEC
Nov 2017$7 MPrivate placement after listing$2 to $10 million5equitySEC
May 2017$1 MPrivate placement after listingUnder $2 million3equitySEC
Jun 2016$5 MPrivate placement after listing$2 to $10 million3equitySEC
Sep 2013$10 MPrivate placement after listing$2 to $10 million1equity, debtSEC
Jul 2012$13 MNo. 5$10 to $50 million53equitySEC
Jun 2012$6 MNo. 4$2 to $10 million1equitySEC
Mar 2012$11 MNo. 3$10 to $50 million1equity, debt, optionsSEC
Jul 2010$2 MNo. 2$2 to $10 million1equity, debtSEC
Dec 2009$3 MNo. 1$2 to $10 million9equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Oragenics, Inc.#

$20 K spent on lobbying the US Congress and federal agencies in 2021, most often on defense.

Lobbying, 2021
$20 K
#1,331 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2021
2026 so far
—
  • Defense3 reports

Lobbying firms hired in 2021

American Defense International, Inc. $20 K

Oragenics, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2021$20 K—4
2020$180 K—5

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Oragenics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Oragenics, Inc. compares in Biotechnology

  • Revenue growth-69.2% · higher than 10% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Oragenics, Inc.🇺🇸$18 M——-69.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Dec 25, 2022 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Oragenics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Oragenics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Oragenics, Inc.? Suggest a correction